| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
CAY10404 is novel, and highly selective inhibitor of COX-
| ln Vitro |
CAY10404 (compound 7) does not inhibit COX-1 (IC50>500 µM)[1]. With a mean 50% inhibitory concentration (IC50) of 60-100 µM, CAY10404 (10-100 µM; for 3 days) suppresses the development of NSCLC cell lines in a concentration-dependent manner [3]. For three days, CAY10404 (20–100 µM) causes NSCLC cells to undergo apoptosis [3]. The concentration-dependent reduction in the levels of pAkt, pGSK-3β, and anti-apoptotic proteins (Bcl-2 and Bcl-XL) is induced by CAY10404 (80 µM) over three days [3]. The ability of H460 cells to form colonies in anchorage-independent growth is inhibited in a concentration-dependent manner by CAY10404 (20, 50, 80, and 100 µM; for 14 days) [3].
|
|---|---|
| ln Vivo |
In HTV mice, the intraperitoneal injection of 50 mg/kg/day of CAY10404 ameliorates lung inflammation and ventilator-induced lung damage [2].
|
| Cell Assay |
Cell Viability Assay [3]
Cell Types: Non-small cell lung cancer (NSCLC) cells (H1703, H358, H460) Tested Concentrations: 10-100 µM Incubation Duration: 3 days Experimental Results: Inhibited the growth of NSCLC cell lines in a certain concentration-dependent manner. Apoptosis analysis[3] Cell Types: H460 Cell Tested Concentrations: 20, 50, 100 µM Incubation Duration: 3 days Experimental Results: Induction of apoptosis. Western Blot Analysis [3] Cell Types: NSCLC cells (H358, H460) Tested Concentrations: 80 µM Incubation Duration: 3 days Experimental Results: Concentration-dependent decrease in the levels of induced anti-apoptotic proteins (Bcl-2 and Bcl-XL) and pAkt and pGSK-3β without changing the levels of pro-apoptotic protein (Bax) and total Akt and GSK-3β protein levels. |
| Animal Protocol |
Animal/Disease Models: Adult male C57Bl/6J mice, body weight 24-30 g[2]
Doses: 50 mg/kg Route of Administration: IP; daily; continued for 4 days Experimental Results: Cyclooxygenase activity diminished, BAL PGE2 and 6 -ketone PGF1α was Dramatically diminished. Reduces lung inflammation (climax volume; 20 ml/kg; 4 hrs (hrs (hours)) duration) and ventilator-induced lung injury in HTV mice. |
| References |
|
| Additional Infomation |
Isoxazole, 3-[4-(methylsulfonyl)phenyl]-4-phenyl-5-(trifluoromethyl)- is a sulfonic acid derivative.
|
| Molecular Formula |
C17H12NO3F3S
|
|---|---|
| Molecular Weight |
367.342
|
| Exact Mass |
367.049
|
| Elemental Analysis |
C, 55.58; H, 3.29; F, 15.52; N, 3.81; O, 13.07; S, 8.73
|
| CAS # |
340267-36-9
|
| PubChem CID |
10429020
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
498.6±45.0 °C at 760 mmHg
|
| Melting Point |
196.47 °C(Predicted)
|
| Flash Point |
255.3±28.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.538
|
| LogP |
2.92
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
547
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CS(=O)(=O)C1=CC=C(C=C1)C2=NOC(=C2C3=CC=CC=C3)C(F)(F)F
|
| InChi Key |
KKBWWVXRKULXHF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H12F3NO3S/c1-25(22,23)13-9-7-12(8-10-13)15-14(11-5-3-2-4-6-11)16(24-21-15)17(18,19)20/h2-10H,1H3
|
| Chemical Name |
3-[4-(Methylsulfonyl)phenyl]-4-phenyl-5-(trifluoromethyl)-isoxazole
|
| Synonyms |
CAY 10404; CAY-10404; CAY10404
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~272.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.81 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.81 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7223 mL | 13.6114 mL | 27.2227 mL | |
| 5 mM | 0.5445 mL | 2.7223 mL | 5.4445 mL | |
| 10 mM | 0.2722 mL | 1.3611 mL | 2.7223 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA